These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 8488549)
1. Controversies in transfusion medicine. Blood banks should use good manufacturing practices and the pharmaceutical manufacturing approach [corrected]. Miller WV Transfusion; 1993 May; 33(5):435-8. PubMed ID: 8488549 [No Abstract] [Full Text] [Related]
2. Controversies in transfusion medicine. The recent emphasis on good manufacturing practices and the pharmaceutical manufacturing approach damages blood banking and transfusion medicine as medical care activities [corrected]. Menitove JE Transfusion; 1993 May; 33(5):439-42. PubMed ID: 8488550 [No Abstract] [Full Text] [Related]
4. Current good manufacturing practices for transfusion medicine. Sazama K Transfus Med Rev; 1996 Oct; 10(4):286-95. PubMed ID: 8899957 [TBL] [Abstract][Full Text] [Related]
5. Revisiting Factor VIII cases: is it time for an agency adjudication system? Su YC Food Drug Law J; 2008; 63(4):943-61. PubMed ID: 19601390 [No Abstract] [Full Text] [Related]
6. AABB and FDA: a shared history of patient safety. Lipton KS; Otter J Transfusion; 2010 Aug; 50(8):1643-6. PubMed ID: 20931688 [No Abstract] [Full Text] [Related]
7. The value of Good Manufacturing Practice to a Blood Service in managing the delivery of quality. Slopecki A; Smith K; Moore S Vox Sang; 2007 Apr; 92(3):187-96. PubMed ID: 17348867 [TBL] [Abstract][Full Text] [Related]
8. Blood & politics. Titus K CAP Today; 1996 Mar; 10(3):20, 22-4. PubMed ID: 10160264 [No Abstract] [Full Text] [Related]
11. Current good manufacturing practices for blood and blood components: notification of consignees receiving blood and blood components at increased risk for transmitting HIV infection--FDA. Final rule. Fed Regist; 1996 Sep; 61(175):47413-23. PubMed ID: 10160337 [TBL] [Abstract][Full Text] [Related]
12. Letter to manufacturers of blood establishment computer software products--FDA. Notice. Fed Regist; 1994 Aug; 59(168):44991-2. PubMed ID: 10136917 [TBL] [Abstract][Full Text] [Related]
13. Hepatitis C screening and notification: hospitals under new FDA regulations. Thomas M; Favata-Bosh DM QRC Advis; 1999 Jan; 15(3):1-5. PubMed ID: 10345516 [No Abstract] [Full Text] [Related]
14. Current good manufacturing practice for blood and blood components; notification of consignees and transfusion recipients receiving blood and blood components at increased risk of transmitting hepatitis C virus infection ("lookback"). Final rule. Food and Drug Administration, HHS Fed Regist; 2007 Aug; 72(164):48765-801. PubMed ID: 17886394 [TBL] [Abstract][Full Text] [Related]
15. Requirements for blood and blood components intended for transfusion or for further manufacturing use. Final rule. Food and Drug Administration, HHS Fed Regist; 2015 May; 80(99):29841-906. PubMed ID: 26003966 [TBL] [Abstract][Full Text] [Related]
17. Doctors not to blame over HIV infection by tainted blood. Wadman M Nature; 2007 Oct; 449(7163):644-5. PubMed ID: 17968385 [No Abstract] [Full Text] [Related]